Nov 11th 2015, 1:00 pm ET

Join us Wednesday, November 11th at 1pm ET to learn more about the importance of myostatin inhibition research. This webinar will help to put context and clarity around this treatment pathway so families have a better understanding as they see clinical trials in this area. 

About Myostatin Inhibition:
Scientists have long theorized that the body normally contains compounds that limit muscle growth. For example, certain breeds of cattle develop substantially more muscle than ordinary cattle.

Researchers have isolated the cause of this disparity to a mutation in the gene that codes for the production of a hormone called myostatin, which tends to limit muscle growth. Scientists searching for a treatment theorize that inhibiting myostatin in boys with Duchenne will cause them to develop more muscle mass initially.

Ideally, this surplus will offset the muscle loss associated with Duchenne, allowing boys to retain their ability to function for a longer period of time.

Speakers:

• Pat Furlong and John Porter, PhD
  Parent Project Muscular Dystrophy
• H.Lee Sweeney, PhD

  Director, UF Myology Institute
  Professor and Thomas H. Maren Eminent Scholar Chair
  Department of Pharmacology & Therapeutics
  University of Florida

To Participate:

1. Visit ReadyTalk.com and use participant code 9449985. (Be sure to test your computer beforehand)
2. Audio Dial-In Information:
   • U.S. & Canada: Dial 1.866.740.1260 and use the Access Code 9449985
   • Outside the U.S. and Canada: Lookup your number

Submit Questions:

Please submit questions in advance to info@parentprojectmd.org (subject line: Myostatin Webinar) by Monday, 11/9 at noon eastern.

Thank You to Our Partners:

This educational webinar on myostatin inhibition is supported in part by Bristol-Myers Squibb and Pfizer, Inc.